The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults.

Weaver JU, Monson JP, Noonan K, John WG, Edwards A, Evans KA, Cunningham J

The Journal of clinical endocrinology and metabolism1 Jan 1995Cited by 173 (Europe PMC)

PMID7829604DOI10.1210/jcem.80.1.7829604PepBankPUB-07829604

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanNon-randomized trialEfficacy outcome
In hypopituitary adults, GH reduced total fat after 6 months (P < 0.02).
In plain wordsIn hypopituitary adults, total fat decreased during GH treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseTotal fat
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Mean 0.2 IU/kg.week · 6 monthsAs given in this study (human).
Measurements
P value
< 0.02
total fat change after 6 months of GH
Source sentences
Summary
GH treatment for 6 months led to a reduction in total fat (P < 0.02), percent fat (P = 0.002), central fat (P = 0.012), waist/hip ratio (P < 0.05), total cholesterol (P = 0.03), and apolipoprotein-B (P = 00001), as well as a decrease in the IS from 36.9% (range, 12-100%) to 25% (range, 2.5-55%; P = 0.0002).
2 context sentences(design, population, supporting numbers)
Summary · context
We report the effect of partially treated hypopituitarism and subsequent GH replacement (mean dose, 0.2 IU/kg.week) on putative cardiovascular risk factors in 22 nondiabetic hypopituitary subjects in a 6-month, double blind, controlled study (active/placebo ratio, 11:11).
Summary · context
All patients were subsequently treated with GH for a further 6 months.
Report a problemFND-0782960401
02HumanNon-randomized trialEfficacy outcome
In hypopituitary adults, GH reduced percent fat after 6 months (P = 0.002).
In plain wordsIn hypopituitary adults, percentage fat decreased during GH treatment.
Peptide
HGH (somatotropin)
Outcome
DecreasePercent fat
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Mean 0.2 IU/kg.week · 6 monthsAs given in this study (human).
Measurements
P value
0.002
percent fat change after 6 months of GH
Source sentences
Summary
GH treatment for 6 months led to a reduction in total fat (P < 0.02), percent fat (P = 0.002), central fat (P = 0.012), waist/hip ratio (P < 0.05), total cholesterol (P = 0.03), and apolipoprotein-B (P = 00001), as well as a decrease in the IS from 36.9% (range, 12-100%) to 25% (range, 2.5-55%; P = 0.0002).
2 context sentences(design, population, supporting numbers)
Summary · context
We report the effect of partially treated hypopituitarism and subsequent GH replacement (mean dose, 0.2 IU/kg.week) on putative cardiovascular risk factors in 22 nondiabetic hypopituitary subjects in a 6-month, double blind, controlled study (active/placebo ratio, 11:11).
Summary · context
All patients were subsequently treated with GH for a further 6 months.
Report a problemFND-0782960402
03HumanNon-randomized trialEfficacy outcome
In hypopituitary adults, GH reduced central fat after 6 months (P = 0.012).
In plain wordsIn hypopituitary adults, central fat decreased during GH treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseCentral fat
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Mean 0.2 IU/kg.week · 6 monthsAs given in this study (human).
Measurements
P value
0.012
central fat change after 6 months of GH
Source sentences
Summary
GH treatment for 6 months led to a reduction in total fat (P < 0.02), percent fat (P = 0.002), central fat (P = 0.012), waist/hip ratio (P < 0.05), total cholesterol (P = 0.03), and apolipoprotein-B (P = 00001), as well as a decrease in the IS from 36.9% (range, 12-100%) to 25% (range, 2.5-55%; P = 0.0002).
2 context sentences(design, population, supporting numbers)
Summary · context
We report the effect of partially treated hypopituitarism and subsequent GH replacement (mean dose, 0.2 IU/kg.week) on putative cardiovascular risk factors in 22 nondiabetic hypopituitary subjects in a 6-month, double blind, controlled study (active/placebo ratio, 11:11).
Summary · context
All patients were subsequently treated with GH for a further 6 months.
Report a problemFND-0782960403
04HumanNon-randomized trialEfficacy outcome
In hypopituitary adults, GH reduced waist/hip ratio after 6 months (P < 0.05).
In plain wordsIn hypopituitary adults, waist/hip ratio decreased during GH treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseWaist/hip ratio
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Mean 0.2 IU/kg.week · 6 monthsAs given in this study (human).
Measurements
P value
< 0.05
waist/hip ratio change after 6 months of GH
Source sentences
Summary
GH treatment for 6 months led to a reduction in total fat (P < 0.02), percent fat (P = 0.002), central fat (P = 0.012), waist/hip ratio (P < 0.05), total cholesterol (P = 0.03), and apolipoprotein-B (P = 00001), as well as a decrease in the IS from 36.9% (range, 12-100%) to 25% (range, 2.5-55%; P = 0.0002).
2 context sentences(design, population, supporting numbers)
Summary · context
We report the effect of partially treated hypopituitarism and subsequent GH replacement (mean dose, 0.2 IU/kg.week) on putative cardiovascular risk factors in 22 nondiabetic hypopituitary subjects in a 6-month, double blind, controlled study (active/placebo ratio, 11:11).
Summary · context
All patients were subsequently treated with GH for a further 6 months.
Report a problemFND-0782960404
05HumanNon-randomized trialEfficacy outcome
In hypopituitary adults, GH reduced total cholesterol after 6 months (P = 0.03).
In plain wordsIn hypopituitary adults, total cholesterol decreased during GH treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseTotal cholesterol
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
Mean 0.2 IU/kg.week · 6 monthsAs given in this study (human).
Measurements
P value
0.03
total cholesterol change after 6 months of GH
Source sentences
Summary
GH treatment for 6 months led to a reduction in total fat (P < 0.02), percent fat (P = 0.002), central fat (P = 0.012), waist/hip ratio (P < 0.05), total cholesterol (P = 0.03), and apolipoprotein-B (P = 00001), as well as a decrease in the IS from 36.9% (range, 12-100%) to 25% (range, 2.5-55%; P = 0.0002).
2 context sentences(design, population, supporting numbers)
Summary · context
We report the effect of partially treated hypopituitarism and subsequent GH replacement (mean dose, 0.2 IU/kg.week) on putative cardiovascular risk factors in 22 nondiabetic hypopituitary subjects in a 6-month, double blind, controlled study (active/placebo ratio, 11:11).
Summary · context
All patients were subsequently treated with GH for a further 6 months.
Report a problemFND-0782960405
06HumanNon-randomized trialEfficacy outcome
In hypopituitary adults, GH reduced apolipoprotein-B after 6 months (P = 00001).
In plain wordsIn hypopituitary adults, apolipoprotein-B decreased during GH treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseApolipoprotein-B
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
Mean 0.2 IU/kg.week · 6 monthsAs given in this study (human).
Source sentences
Summary
GH treatment for 6 months led to a reduction in total fat (P < 0.02), percent fat (P = 0.002), central fat (P = 0.012), waist/hip ratio (P < 0.05), total cholesterol (P = 0.03), and apolipoprotein-B (P = 00001), as well as a decrease in the IS from 36.9% (range, 12-100%) to 25% (range, 2.5-55%; P = 0.0002).
2 context sentences(design, population, supporting numbers)
Summary · context
We report the effect of partially treated hypopituitarism and subsequent GH replacement (mean dose, 0.2 IU/kg.week) on putative cardiovascular risk factors in 22 nondiabetic hypopituitary subjects in a 6-month, double blind, controlled study (active/placebo ratio, 11:11).
Summary · context
All patients were subsequently treated with GH for a further 6 months.
Report a problemFND-0782960406
07HumanNon-randomized trialEfficacy outcome
In hypopituitary adults, GH reduced insulin sensitivity from 36.9% (12-100%) to 25% (2.5-55%) after 6 months (P = 0.0002).
In plain wordsIn hypopituitary adults, insulin sensitivity decreased during GH treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseInsulin sensitivity
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Mean 0.2 IU/kg.week · 6 monthsAs given in this study (human).
Measurements
Insulin sensitivity
36.9%
before GH
Insulin sensitivity
12 to 100%
before GH, range
Insulin sensitivity
25%
after 6 months of GH
Insulin sensitivity
2.5 to 55%
after 6 months of GH, range
P value
0.0002
insulin sensitivity change
Source sentences
Summary
GH treatment for 6 months led to a reduction in total fat (P < 0.02), percent fat (P = 0.002), central fat (P = 0.012), waist/hip ratio (P < 0.05), total cholesterol (P = 0.03), and apolipoprotein-B (P = 00001), as well as a decrease in the IS from 36.9% (range, 12-100%) to 25% (range, 2.5-55%; P = 0.0002).
2 context sentences(design, population, supporting numbers)
Summary · context
We report the effect of partially treated hypopituitarism and subsequent GH replacement (mean dose, 0.2 IU/kg.week) on putative cardiovascular risk factors in 22 nondiabetic hypopituitary subjects in a 6-month, double blind, controlled study (active/placebo ratio, 11:11).
Summary · context
All patients were subsequently treated with GH for a further 6 months.
Report a problemFND-0782960407
08HumanNon-randomized trialEfficacy outcome
In hypopituitary adults, fasting total insulin increased during GH treatment (P = 0.016).
In plain wordsIn hypopituitary adults, fasting total insulin increased during GH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseFasting total insulin
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Mean 0.2 IU/kg.week · 6 monthsAs given in this study (human).
Measurements
P value
0.016
fasting total insulin change
Source sentences
Summary
This was paralleled by a rise in fasting (total) and specific insulin (P = 0.016 and P = 0.002).
2 context sentences(design, population, supporting numbers)
Summary · context
We report the effect of partially treated hypopituitarism and subsequent GH replacement (mean dose, 0.2 IU/kg.week) on putative cardiovascular risk factors in 22 nondiabetic hypopituitary subjects in a 6-month, double blind, controlled study (active/placebo ratio, 11:11).
Summary · context
All patients were subsequently treated with GH for a further 6 months.
Report a problemFND-0782960408
09HumanNon-randomized trialEfficacy outcome
In hypopituitary adults, fasting specific insulin increased during GH treatment (P = 0.002).
In plain wordsIn hypopituitary adults, fasting specific insulin increased during GH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseFasting specific insulin
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Mean 0.2 IU/kg.week · 6 monthsAs given in this study (human).
Measurements
P value
0.002
fasting specific insulin change
Source sentences
Summary
This was paralleled by a rise in fasting (total) and specific insulin (P = 0.016 and P = 0.002).
2 context sentences(design, population, supporting numbers)
Summary · context
We report the effect of partially treated hypopituitarism and subsequent GH replacement (mean dose, 0.2 IU/kg.week) on putative cardiovascular risk factors in 22 nondiabetic hypopituitary subjects in a 6-month, double blind, controlled study (active/placebo ratio, 11:11).
Summary · context
All patients were subsequently treated with GH for a further 6 months.
Report a problemFND-0782960409
10HumanNon-randomized trialMechanism
In hypopituitary adults, correlations among insulin sensitivity, body composition and fat distribution indices increased after GH treatment.
In plain wordsIn hypopituitary adults, correlations among insulin sensitivity and body composition indices increased after GH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseCorrelations among insulin sensitivity and body composition indices
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Mean 0.2 IU/kg.week · 6 monthsAs given in this study (human).
Source sentences
Summary
The degree of correlation among indices of IS, body composition, and fat distribution increased after GH treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
We report the effect of partially treated hypopituitarism and subsequent GH replacement (mean dose, 0.2 IU/kg.week) on putative cardiovascular risk factors in 22 nondiabetic hypopituitary subjects in a 6-month, double blind, controlled study (active/placebo ratio, 11:11).
Summary · context
All patients were subsequently treated with GH for a further 6 months.
Report a problemFND-0782960410
11HumanNon-randomized trialEfficacy outcome
In hypopituitary adults, fasting plasma glucose rose significantly during GH treatment but remained within the reference range.
In plain wordsIn hypopituitary adults, fasting glucose increased during GH treatment but stayed within the reference range.
Peptide
HGH (somatotropin)
Outcome
IncreaseFasting plasma glucose
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Mean 0.2 IU/kg.week · 6 monthsAs given in this study (human).
Source sentences
Summary
Fasting plasma glucose rose significantly, but was within the reference range.
2 context sentences(design, population, supporting numbers)
Summary · context
We report the effect of partially treated hypopituitarism and subsequent GH replacement (mean dose, 0.2 IU/kg.week) on putative cardiovascular risk factors in 22 nondiabetic hypopituitary subjects in a 6-month, double blind, controlled study (active/placebo ratio, 11:11).
Summary · context
All patients were subsequently treated with GH for a further 6 months.
Report a problemFND-0782960411
12HumanNon-randomized trialEfficacy outcome
In hypopituitary adults, serum lipoprotein-(a) increased significantly during 12 months of GH therapy (P < 0.05).
In plain wordsIn hypopituitary adults, lipoprotein-(a) increased during 12 months of GH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseSerum lipoprotein-(a)
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
Mean 0.2 IU/kg.week · 12 monthsAs given in this study (human).
Measurements
P value
< 0.05
serum lipoprotein-(a) increase over 12 months of GH
Source sentences
Summary
During 12 months of GH therapy, a significant increase in serum lipoprotein-(a) was observed (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
We report the effect of partially treated hypopituitarism and subsequent GH replacement (mean dose, 0.2 IU/kg.week) on putative cardiovascular risk factors in 22 nondiabetic hypopituitary subjects in a 6-month, double blind, controlled study (active/placebo ratio, 11:11).
Summary · context
All patients were subsequently treated with GH for a further 6 months.
Report a problemFND-0782960412

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT00136032

Growth Hormone Administration and Its Effects on Cardiovascular Risk Factors in Growth Hormone Deficient Women

Massachusetts General Hospitaln = 63Jan 2002 to Nov 2006

Growth Hormone Deficiency

Trial page ClinicalTrials.govUpdated 18 Feb 2008

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.